Azienda Sanitaria Locale Di Pescara

The UO di Oncoematologia Pediatrica at Azienda Sanitaria Locale Di Pescara is highly active in hematologic malignancies, with studies focused on acute leukemias, lymphomas, and multiple myeloma. These trials mainly aim to improve remission rates, reduce relapse, and test newer treatment combinations for both children and adults.

• Acute lymphoblastic leukemia, acute myeloid leukemia, and lymphoblastic lymphoma
• Diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma
• Multiple myeloma, smoldering myeloma, and myelodysplastic syndromes

Research here often explores whether newer immunotherapies, targeted medicines, and transplant-related strategies can improve disease control and long-term outcomes.

This site also supports a strong program in pediatric oncology, especially for acute lymphoblastic leukemia and Langerhans cell histiocytosis. The trials are designed to refine treatment approaches, improve response rates, and lower the chance of relapse or late complications in younger patients.

• Childhood and adolescent acute lymphoblastic leukemia
• Very high-risk T-lineage disease and Philadelphia chromosome-positive subtypes
• Langerhans cell histiocytosis with efforts to reduce reactivation and long-term sequelae

Several studies focus on making treatment more effective while also aiming to preserve quality of life for children and teenagers.

Clinical research at Azienda Sanitaria Locale Di Pescara includes immune system diseases such as ulcerative colitis, Crohn’s disease, systemic lupus erythematosus, and systemic sclerosis. These trials are largely intended to evaluate new therapies, improve symptom control, and support better long-term disease management.

• Moderately to severely active ulcerative colitis and Crohn’s disease
• Refractory systemic lupus erythematosus and lupus nephritis
• Diffuse cutaneous systemic sclerosis

The research also includes studies of treatment safety and effectiveness in patients with difficult-to-control inflammatory conditions.

The site contributes to studies in cardiovascular diseases and nutritional and metabolic diseases, including acute myocardial infarction, type 2 diabetes mellitus, and broader metabolic risk management. These trials are aimed at improving prevention, treatment effectiveness, and recovery after major cardiovascular events.

• Acute myocardial infarction and related cardiovascular risk reduction
• Type 2 diabetes mellitus and glycemic control
• Metabolic disease management in older and medically complex patients

Some research also examines how treatment strategies can better support real-world care and reduce future complications.

Research in digestive system diseases and neoplasms includes ulcerative colitis, colorectal cancer, and gastric or gastroesophageal cancer. The main purpose of these trials is to test better treatment approaches, monitor disease response, and improve outcomes in both inflammatory and cancer settings.

• Metastatic colorectal cancer and gastric or gastroesophageal cancer
• Inflammatory bowel disease with pediatric and adult populations
• Biomarker-driven strategies to guide treatment selection and response assessment

These studies reflect an interest in combining clinical benefit with more personalized care for digestive tract conditions.

The site also participates in analytical, diagnostic and therapeutic techniques and equipment research, with a focus on improving how disease is detected, monitored, and treated. Much of this work centers on minimal residual disease, molecular relapse, and other response markers used to guide more precise care.

• MRD monitoring in leukemia, lymphoma, and myeloma
• ctDNA and biomarker-based assessment in cancer care
• Studies of treatment response to support more tailored therapy choices

These investigations are important for identifying who may benefit most from a given treatment and for tracking effectiveness over time.

Several trials at this site examine hematopoietic stem cell transplantation, infection prevention, and other supportive strategies in patients with blood cancers. The goal is to improve treatment tolerance, reduce complications, and help more patients reach effective disease control.

• Transplant-eligible and transplant-ineligible blood cancer populations
• Infection prophylaxis in patients with secondary immunodeficiency
• Studies of chronic graft-versus-host disease and treatment support after intensive therapy

This research highlights a strong interest in safer, more effective care across the full treatment journey.